Most Clicked AABB SmartBrief Stories


1. Study examines bleeding risks of NSAIDS combined with anti-clotting drugs

AABB SmartBrief | Feb 25, 2015

Taking nonsteroidal anti-inflammatory drugs with antithrombotic drugs was associated with increased risk of major bleeding, a second heart attack and death for patients with a history of heart attacks, according to a study in the Journal of the American Medical Association. An analysis of the records of more than 60,000 heart attack survivors found bleeding events were about twice as likely for patients who had taken an NSAID along with clot-preventing drugs. Reuters (02/24)


2. Pathogen reduction technologies featured in February issue of AABB News

AABB SmartBrief | Feb 24, 2015

The February issue of AABB News highlights the use of pathogen reduction, or PR, technologies to prevent the spread of infectious diseases. One article in the issue describes how researchers and clinicians are using these technologies in Puerto Rico to reduce the risk of spreading chikungunya and dengue viruses through blood products. In December, FDA approved the first pathogen reduction system for platelets and plasma authorized for use in the United States. A second article focuses on research aimed at treating whole blood with PR technologies to use in circumstances where only unscreened whole blood is available, such as military deployments. Blank (02/24)


3. Dental stem cells converted into corneal stromal cells

AABB SmartBrief | Feb 24, 2015

University of Pittsburgh ophthalmology researchers have converted stem cells extracted from the dental pulp of wisdom teeth into corneal stromal cells, according to a study in the journal Stem Cells Translational Medicine. The study team transplanted the cells into the corneas of healthy mice. Genetic Engineering & Biotechnology News (02/23) FoxNews.com (02/23)


4. Retinal tissue developed from stem cells, researchers report

AABB SmartBrief | Feb 23, 2015

Scientists at the Riken Center for Developmental Biology and Sumitomo Chemical have devised a method of engineering three-dimensional retinal tissue from human stem cells. The cultured tissue included the ciliary margin, where stem cells produce photoreceptor and nerve cells. The results of the study were reported in the journal Nature Communications. Japan Times, The (02/20)


5. Upcoming audioconference discusses clinical practice guidelines for platelet transfusions

AABB SmartBrief | Feb 27, 2015

On Tuesday, March 3, AABB's audioconference, "Guidelines for Platelet Use," will discuss the November 2014 publication of clinical practice guidelines for platelet transfusions. Based on a systematic review of available data and developed pursuant to the widely recognized GRADE methodology, these evidence-based guidelines are designed to provide clinicians with valuable guidance regarding when and at what dose to transfuse platelets in a variety of patient populations. These populations include individuals with hypoproliferative thrombocytopenia and patients undergoing procedures such as elective central venous catheter placement, lumbar puncture and major, elective, non-neuraxial surgery and coronary artery bypass graft surgery. Blank (02/27)


6. Stem cell study examines prevalence of leukemia-related mutations by age

AABB SmartBrief | Feb 27, 2015

Researchers in the U.K. have found that about 20% of people ages 50 to 60 and more than 70% of people older than 90 had leukemia-related mutations in blood stem cells, according to a study in the journal Cell Reports. The findings were based on an analysis of cell samples from 4,200 healthy people. HealthDay News (02/26) Independent (London) (tiered subscription model), The (02/26)


7. Drug shows efficacy in addressing infantile hemangioma

AABB SmartBrief | Feb 23, 2015

Data on 460 infants with infantile hemangioma showed 88% of those treated with propranolol exhibited improvements at five weeks, compared with 5% of those on placebo treatment. Sixty percent of patients in the treatment group had their birthmarks almost or completely disappear, compared with only 4% in the placebo cohort. The results appear in the New England Journal of Medicine. PhysiciansBriefing.com (02/19)


8. Clostridium difficile germinates in digestive tract within 24 hours

AABB SmartBrief | Feb 24, 2015

Researchers have found that Clostridium difficile spores develop into toxin-producing, diarrhea-inducing cells in the large intestine of antibiotic-treated mice within 24 hours. The study, which appeared in the journal Infection and Immunity, found that C. difficile became the most dominant gut bacteria within 36 hours of exposure in mice whose bacterial colonies had been disrupted by antibiotics. Medical News Today (02/23)


9. Portola's factor Xa inhibitor antidote receives FDA orphan designation

AABB SmartBrief | Feb 27, 2015

Portola Pharmaceuticals' experimental drug andexanet alfa received orphan drug status from the FDA for use in reversing the anticoagulant effect of direct or indirect factor Xa inhibitors in patients experiencing serious uncontrolled bleeding or needing emergency surgical procedures. The drug is being evaluated in two late-stage trials. Healio (free registration) (02/26)


10. Reminder: PBM learning modules now available

AABB SmartBrief | Feb 26, 2015

Four PBM learning modules are now available. These modules include Patient Blood Management Module: Introduction; Optimizing Transfusion Benefits: Recognizing When Transfusions Are Helpful; Intraoperative Blood Conservation, Transfusion Strategies and Surgical Techniques; and Patient Blood Management for Coagulopathy. The modules provide educational content about PBM, an evidence-based, multidisciplinary approach to optimizing the care of patients who might need a blood transfusion. The modules can help providers determine the best strategies for managing blood-related issues for different patient populations. Interested individuals can purchase the PBM modules -- which are available individually and in institutional packages with multiple licenses -- online. A video about the modules is available, as well. Blank (11/17)




Sign up for AABB SmartBrief



Designed specifically for the transfusion medicine and cellular therapy community, AABB SmartBrief is a FREE, daily e-mail newsletter. It provides a summary of the most important news in our field to members of AABB and beyond. To save time and stay smart, sign up today to receive AABB SmartBrief, free of charge. Learn more